June 30, 1999 -- Minnetonka, MN - LecTec Corporation (Nasdaq National Market: LECT), announced today that it has received two new U.S. patents on cotinine. Cotinine is a non-nicotine, non-addictive compound, and it is the primary metabolite of nicotine. LecTec Corporation has six existing U.S. patents which cover the use of cotinine for smoking cessation and weight management. The first new patent describes a therapeutic method to treat psychiatric disorders such as Obsessive Compulsive Disorder, Tourette's Syndrome and various addictive conditions. The second new patent gives additional patent coverage for cotinine's potential utility as a smoking cessation therapy.

"The issuance of these two new patents coincides with new preliminary evidence suggesting that our cotinine pill may reduce the withdrawal symptoms associated with tobacco cessation. In addition to relieving tobacco withdrawal symptoms, cotinine may also have beneficial effects on symptoms associated with some psychiatric disorders," Rodney A. Young, CEO and President commented.

"The potential benefits of cotinine as an aid in smoking cessation, weight management, and now psychiatric disorders, increase our optimism about the full potential of cotinine. We are seeking co-development/marketing partners to take cotinine through its next phase of clinical development. To accomplish this, we have prepared a well-defined clinical development plan and execution strategy," concluded Young.

LecTec is a health care and consumer products company that develops, manufactures and markets products based on its advanced skin interface technologies. Primary products include diagnostic electrodes and conductive hydrogels for electrocardiography and related applications, a full line of medical tapes, and over-the-counter therapeutic patches.

CONTACT: LecTec Corporation, Minnetonka

Rodney A. Young, CEO
or
Jane M. Nichols, VP Marketing & New
Business Development
612/933-2291
or
800-777-2291